SOUTH SAN FRANCISCO, CA--(Marketwire - February 01, 2010) -
Highlighted Links |
CYTK Website |
Interested parties may access the live audio webcast of these presentations and replays by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of each of the events.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are
not limited to, statements relating to planned presentations, and the
properties and potential benefits of Cytokinetics' drug candidates and
potential drug candidates. Such statements are based on management's
current expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory approval and
production of Cytokinetics' drug candidates and potential drug candidates
that could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials results
and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy.
For further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics' filings with
the Securities and Exchange Commission.
Contacts:
Cytokinetics, Incorporated
Christopher S. Keenan
(Investors and Media)
Director, Investor Relations
(650) 624-3000